Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2018 16:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

CAMBRIDGE, Mass., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
December 06, 2018 21:56 ET | Source: Momenta Pharmaceuticals, Inc.

UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
December 05, 2018 16:15 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
December 03, 2018 16:05 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®

CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing...
November 07, 2018 09:45 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281

Full data shows safety, tolerability and proof-of-mechanism in healthy volunteers CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced...
November 07, 2018 06:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a...
November 06, 2018 16:45 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights for the...
November 06, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. The presentation is...
October 31, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30,...
October 04, 2018 08:00 ET | Source: Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals to Host R&D Day on October 11, 2018

CAMBRIDGE, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right